August 10, 2021
The application for adjuvant pembrolizumab in renal cell carcinoma is supported by data from the phase 3 KEYNOTE-564 trial, which were presented at the 2021 ASCO Annual Meeting.
August 04, 2021
"There is clearly a lot of interest in the urologic oncology world toward bladder preservation for both muscle-invasive bladder cancer as well as early-stage non-muscle-invasive bladder cancer," says Arjun V. Balar, MD.
July 30, 2021
Arjun V. Balar, MD, discusses notable findings from 2 separate studies of pembrolizumab (Keytruda).
July 28, 2021
Arjun V. Balar, MD, describes the 2 “very distinct patient populations” of separate phase 2 studies from ASCO 2021 involving the treatment pembrolizumab (Keytruda).
July 26, 2021
Results from a pooled analysis of frontline treatment in metastatic renal cell carcinoma provided early evidence of a differential overall survival benefit between patients with favorable-risk disease compared to patients with intermediate/poor-risk disease.
July 17, 2021
“The key message from this abstract is that the time duration for starting avelumab [Bavencio] maintenance didn't really affect the outcomes,” says Shilpa Gupta, MD.
July 15, 2021
Shilpa Gupta, MD, discusses several recent studies in the metastatic urothelial carcinoma space.
July 13, 2021
"I think [at] the 2021 ASCO annual meeting, we saw a lot of novel data focusing on bladder-preservation approaches," says Shilpa Gupta, MD.
Miron presented a study at the 2021 ASCO Annual Meeting that explored the influence of first-line chemotherapy choice on survival outcomes in patients who received immunotherapy in the second-line setting.
July 09, 2021
In this video, Shilpa Gupta, MD, discusses the rapidly evolving world of research on urothelial carcinoma.
